184 related articles for article (PubMed ID: 7932591)
1. Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.
Tokarski JS; Hopfinger AJ
J Med Chem; 1994 Oct; 37(21):3639-54. PubMed ID: 7932591
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
Sinha J; Kurup A; Paleti A; Gupta SP
Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
[TBL] [Abstract][Full Text] [Related]
3. Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.
Bhattacharya P; Leonard JT; Roy K
J Mol Model; 2005 Nov; 11(6):516-24. PubMed ID: 15928917
[TBL] [Abstract][Full Text] [Related]
4. A molecular shape analysis and quantitative structure-activity relationship investigation of some triazine-antifolate inhibitors of Leishmania dihydrofolate reductase.
Koehler MG; Rowberg-Schaefer K; Hopfinger AJ
Arch Biochem Biophys; 1988 Oct; 266(1):152-61. PubMed ID: 3178219
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
6. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
[TBL] [Abstract][Full Text] [Related]
7. Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors.
Burke BJ; Dunn WJ; Hopfinger AJ
J Med Chem; 1994 Oct; 37(22):3775-88. PubMed ID: 7966137
[TBL] [Abstract][Full Text] [Related]
8. A 3D-QSAR study of anticoccidial triazines using molecular shape analysis.
Rhyu KB; Patel HC; Hopfinger AJ
J Chem Inf Comput Sci; 1995; 35(4):771-8. PubMed ID: 7657731
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-activity relationship studies on 5-phenyl-3-ureido-1,5-benzodiazepine as cholecystokinin-A receptor antagonists.
Agrawal VK; Sharma R; Khadikar PV
Bioorg Med Chem; 2002 Nov; 10(11):3571-81. PubMed ID: 12213472
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationship studies on cholecystokinin antagonists.
Gupta SP
Curr Pharm Des; 2002; 8(2):111-24. PubMed ID: 11812253
[TBL] [Abstract][Full Text] [Related]
11. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Tabuchi S; Nakanishi I; Satoh Y
Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
13. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
[TBL] [Abstract][Full Text] [Related]
14. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
15. Comparative molecular field analysis of CCK-A antagonists using field-fit as an alignment technique. A convenient guide to design new CCK-A ligands.
Rault S; Bureau R; Pilo JC; Robba M
J Comput Aided Mol Des; 1992 Dec; 6(6):553-68. PubMed ID: 1291625
[TBL] [Abstract][Full Text] [Related]
16. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
Roy K; Leonard JT
J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
[TBL] [Abstract][Full Text] [Related]
17. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.
Lowe JA; Hageman DL; Drozda SE; McLean S; Bryce DK; Crawford RT; Zorn S; Morrone J; Bordner J
J Med Chem; 1994 Oct; 37(22):3789-811. PubMed ID: 7966138
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
19. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
20. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.
Satoh M; Kondoh Y; Okamoto Y; Nishida A; Miyata K; Ohta M; Mase T; Murase K
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2159-67. PubMed ID: 8582018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
